Beta Bionics Inc. (BBNX) Insider Trading

Last 12 months

Insiders sold $4.55M and bought nothing on the open market.

67% of the selling was scheduled in advance under 10b5-1 plans. The last open-market buy by an executive or director was in Jan 2025.

Net open-market

−$4.55M

0 buys · 43 sales

Under a 10b5-1 plan

67%

of the value sold

Insiders who bought / sold

0 / 8

executives and directors

Last open-market buy

Jan 2025

Jan 31, 2025

Get an email when BBNX's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Oct 14	Mark Hopman Chief Commercial Officer	Sold10b5-1 plan	775	$17.35	$13k	1.4%	Form 4
Oct 1	Mark Hopman Chief Commercial Officer	Sold10b5-1 plan	370	$18.96	$7k	0.7%	Form 4
Sep 22	Christy Jones Director	Sold10b5-1 plan	6,430	$23.00	$148k	25%	Form 4
Sep 16	Mike Mensinger Chief Product Officer	Sold10b5-1 plan	2,650	$22.00	$58k	1.5%	Form 4
Sep 16	Mark Hopman Chief Commercial Officer	Sold10b5-1 plan	30,779	$20.13	$620k	35%	Form 4
Sep 14	Mark Hopman Chief Commercial Officer	Sold10b5-1 plan	775	$15.52	$12k	0.9%	Form 4
Sep 9	Mark Hopman Chief Commercial Officer	Sold10b5-1 plan	35,994	$18.46	$664k	29%	Form 4
Sep 3	Sean Saint President & CEO	Sold10b5-1 plan	5,641	$20.08	$113k	1.4%	Form 4
Sep 2	Steven Jon Russell Chief Medical Officer	SoldNo plan	4,221	$19.11	$81k	2.4%	Form 4
Sep 2	Sean Saint President & CEO	SoldNo plan	16,867	$19.11	$322k	4.0%	Form 4
Sep 2	Stephen Feider Chief Financial Officer	SoldNo plan	6,675	$19.11	$128k	4.0%	Form 4
Sep 2	Mike Mensinger Chief Product Officer	SoldNo plan	4,375	$19.11	$84k	2.4%	Form 4
Sep 2	Mark Hopman Chief Commercial Officer	SoldNo plan	5,327	$19.11	$102k	4.1%	Form 4
Jun 26 – 29	Stephen Feider Chief Financial Officer	Sold10b5-1 plan 2 parts	10,000	$17.04 average	$170k	5.7%	Form 4
Jun 24	Mark Hopman Chief Commercial Officer	Sold10b5-1 plan	1,258	$15.01	$19k	1.0%	Form 4
Jun 24	Christy Jones Director	Sold10b5-1 plan	1,406	$15.00	$21k	5.1%	Form 4
Jun 4	Mark Hopman Chief Commercial Officer	Sold10b5-1 plan	275	$12.31	$3k	0.2%	Form 4
Jun 4	Christy Jones Director	Sold10b5-1 plan	2,811	$14.00	$39k	9.3%	Form 4
Jun 2	Steven Jon Russell Chief Medical Officer	SoldNo plan	4,222	$12.61	$53k	2.4%	Form 4
Jun 2	Sean Saint President & CEO	SoldNo plan	16,872	$12.61	$213k	3.9%	Form 4
Jun 2	Stephen Feider Chief Financial Officer	SoldNo plan	6,676	$12.61	$84k	3.9%	Form 4
Jun 2	Mike Mensinger Chief Product Officer	SoldNo plan	4,378	$12.61	$55k	2.3%	Form 4
Jun 2	Mark Hopman Chief Commercial Officer	SoldNo plan	5,329	$12.61	$67k	3.9%	Form 4
May 21 – 22	Adam Lezack Director	Sold10b5-1 plan 2 parts	1,998	$10.58 average	$21k	3.5%	Form 4
May 21	Christy Jones Director	Sold10b5-1 plan	1,998	$9.95	$20k	6.2%	Form 4
Mar 4	Mark Hopman Chief Commercial Officer	Sold10b5-1 plan	353	$11.57	$4k	0.3%	Form 4
Mar 2	Steven Jon Russell Chief Medical Officer	SoldNo plan	1,026	$12.36	$13k	0.6%	Form 4
Mar 2	Sean Saint President & CEO	SoldNo plan	3,384	$12.36	$42k	0.8%	Form 4
Mar 2	Stephen Feider Chief Financial Officer	SoldNo plan	1,428	$12.36	$18k	0.8%	Form 4
Mar 2	Mike Mensinger Chief Product Officer	SoldNo plan	1,064	$12.36	$13k	0.6%	Form 4
Mar 2	Mark Hopman Chief Commercial Officer	SoldNo plan	834	$12.36	$10k	0.6%	Form 4
Jan 6	Mike Mensinger Chief Product Officer	Sold10b5-1 plan	2,200	$30.10	$66k	2.7%	Form 4
Jan 2	Stephen Feider Chief Financial Officer	Sold10b5-1 plan	20,000	$29.53	$591k	32%	Form 4
Jan 2	Mike Mensinger Chief Product Officer	Sold10b5-1 plan 2 parts	7,800	$29.61 average	$231k	8.6%	Form 4
Dec 2, 2025 – Dec 4, 2025	Mark Hopman Chief Commercial Officer	Sold10b5-1 plan 2 parts	2,917	$30.27 average	$88k	2.1%	Form 4
Dec 2, 2025	Steven Jon Russell Chief Medical Officer	SoldNo plan	1,025	$29.34	$30k	0.6%	Form 4
Dec 2, 2025	Sean Saint President & CEO	SoldNo plan	3,278	$29.34	$96k	3.2%	Form 4
Dec 2, 2025	Stephen Feider Chief Financial Officer	SoldNo plan	1,427	$29.34	$42k	3.2%	Form 4
Dec 2, 2025	Mike Mensinger Chief Product Officer	SoldNo plan	1,063	$29.34	$31k	1.2%	Form 4
Dec 1, 2025	Adam Lezack Director	Sold10b5-1 plan 2 parts	1,406	$29.55 average	$42k	14%	Form 4

Oct 1410b5-1 plan
Mark Hopman
Chief Commercial Officer · sold 775 at $17.35
$13k
1.4% of stake
Oct 110b5-1 plan
Mark Hopman
Chief Commercial Officer · sold 370 at $18.96
$7k
0.7% of stake
Sep 2210b5-1 plan
Christy Jones
Director · sold 6,430 at $23.00
$148k
25% of stake
Sep 1610b5-1 plan
Mike Mensinger
Chief Product Officer · sold 2,650 at $22.00
$58k
1.5% of stake
Sep 1610b5-1 plan
Mark Hopman
Chief Commercial Officer · sold 30,779 at $20.13
$620k
35% of stake
Sep 1410b5-1 plan
Mark Hopman
Chief Commercial Officer · sold 775 at $15.52
$12k
0.9% of stake
Sep 910b5-1 plan
Mark Hopman
Chief Commercial Officer · sold 35,994 at $18.46
$664k
29% of stake
Sep 310b5-1 plan
Sean Saint
President & CEO · sold 5,641 at $20.08
$113k
1.4% of stake
Sep 2No plan
Steven Jon Russell
Chief Medical Officer · sold 4,221 at $19.11
$81k
2.4% of stake
Sep 2No plan
Sean Saint
President & CEO · sold 16,867 at $19.11
$322k
4.0% of stake
Sep 2No plan
Stephen Feider
Chief Financial Officer · sold 6,675 at $19.11
$128k
4.0% of stake
Sep 2No plan
Mike Mensinger
Chief Product Officer · sold 4,375 at $19.11
$84k
2.4% of stake
Sep 2No plan
Mark Hopman
Chief Commercial Officer · sold 5,327 at $19.11
$102k
4.1% of stake
Jun 26 – 2910b5-1 plan
Stephen Feider
Chief Financial Officer · sold 10,000 at avg $17.04
$170k
5.7% of stake
Jun 2410b5-1 plan
Mark Hopman
Chief Commercial Officer · sold 1,258 at $15.01
$19k
1.0% of stake
Jun 2410b5-1 plan
Christy Jones
Director · sold 1,406 at $15.00
$21k
5.1% of stake
Jun 410b5-1 plan
Mark Hopman
Chief Commercial Officer · sold 275 at $12.31
$3k
0.2% of stake
Jun 410b5-1 plan
Christy Jones
Director · sold 2,811 at $14.00
$39k
9.3% of stake
Jun 2No plan
Steven Jon Russell
Chief Medical Officer · sold 4,222 at $12.61
$53k
2.4% of stake
Jun 2No plan
Sean Saint
President & CEO · sold 16,872 at $12.61
$213k
3.9% of stake
Jun 2No plan
Stephen Feider
Chief Financial Officer · sold 6,676 at $12.61
$84k
3.9% of stake
Jun 2No plan
Mike Mensinger
Chief Product Officer · sold 4,378 at $12.61
$55k
2.3% of stake
Jun 2No plan
Mark Hopman
Chief Commercial Officer · sold 5,329 at $12.61
$67k
3.9% of stake
May 21 – 2210b5-1 plan
Adam Lezack
Director · sold 1,998 at avg $10.58
$21k
3.5% of stake
May 2110b5-1 plan
Christy Jones
Director · sold 1,998 at $9.95
$20k
6.2% of stake
Mar 410b5-1 plan
Mark Hopman
Chief Commercial Officer · sold 353 at $11.57
$4k
0.3% of stake
Mar 2No plan
Steven Jon Russell
Chief Medical Officer · sold 1,026 at $12.36
$13k
0.6% of stake
Mar 2No plan
Sean Saint
President & CEO · sold 3,384 at $12.36
$42k
0.8% of stake
Mar 2No plan
Stephen Feider
Chief Financial Officer · sold 1,428 at $12.36
$18k
0.8% of stake
Mar 2No plan
Mike Mensinger
Chief Product Officer · sold 1,064 at $12.36
$13k
0.6% of stake
Mar 2No plan
Mark Hopman
Chief Commercial Officer · sold 834 at $12.36
$10k
0.6% of stake
Jan 610b5-1 plan
Mike Mensinger
Chief Product Officer · sold 2,200 at $30.10
$66k
2.7% of stake
Jan 210b5-1 plan
Stephen Feider
Chief Financial Officer · sold 20,000 at $29.53
$591k
32% of stake
Jan 210b5-1 plan
Mike Mensinger
Chief Product Officer · sold 7,800 at avg $29.61
$231k
8.6% of stake
Dec 2, 2025 – Dec 4, 202510b5-1 plan
Mark Hopman
Chief Commercial Officer · sold 2,917 at avg $30.27
$88k
2.1% of stake
Dec 2, 2025No plan
Steven Jon Russell
Chief Medical Officer · sold 1,025 at $29.34
$30k
0.6% of stake
Dec 2, 2025No plan
Sean Saint
President & CEO · sold 3,278 at $29.34
$96k
3.2% of stake
Dec 2, 2025No plan
Stephen Feider
Chief Financial Officer · sold 1,427 at $29.34
$42k
3.2% of stake
Dec 2, 2025No plan
Mike Mensinger
Chief Product Officer · sold 1,063 at $29.34
$31k
1.2% of stake
Dec 1, 202510b5-1 plan
Adam Lezack
Director · sold 1,406 at avg $29.55
$42k
14% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch BBNX, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Related stocks: Surgical & Medical Instruments & Apparatus

ANIKAnika Therapeutics Inc.

XTNTXtant Medical Holdings Inc.

OSUROrasure Technologies Inc.

NPCENeuroPace Inc.

MHUAFMeihua International Medical Technologies Co., Ltd.

INFUInfuSystem Holdings Inc.

KMTSKestra Medical Technologies, Ltd.

DCTHDelcath Systems Inc.

Spot a number that looks wrong? Check it in BBNX's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing BBNX

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.